Investigation the longevity of hepatitis B surface antibody in vaccinated students of Hormozgan university of medical sciences
Abstract
Background and Objectives: Hepatitis B is a common chronic viral infection in humans. Universal use of hepatitis B vaccine is crucial for controlling the infection, but the duration of vaccine-induced immunity remains uncertain. This study aimed to assess hepatitis B antibody levels (anti-HBs) after vaccination in infancy and adolescence, and explore the relationship between immunity levels and variables such as age, sex, BMI, place of birth, and duration since last vaccination among students at Hormozgan University of Medical Sciences from 2019 to 2021.
Materials and Methods: The study included 1134 students who completed a questionnaire and provided blood samples for ELISA-based measurement of antibody titers.
Results: The findings revealed that 727 students (64.1%) had no protective antibody level (anti-HBs <10 mIU/ml), 299 (26.4%) had partial immunity (anti-HBs 10-100 mIU/ml), and 108 (9.5%) had complete immunity (anti-HBs >100 mIU/ml). No statistically significant relationships were observed between anti-HBs titer and age, sex, or BMI. However, antibody titer decreased with increasing time since last vaccination (P<0.001).
Conclusion: This study highlights the decline in antibody titer over time following primary vaccination. Sustained immunity against hepatitis B virus relies on antibody durability or robust immunological memory, suggesting the importance of timing booster vaccinations.
2. Organization WH. Global hepatitis report 2017: World Health Organization; 2017.
3. Khosravani A, Sarkari B, Negahban H, Sharifi A, Toori MA, Eilami O. Hepatitis B Infection among high risk population: a seroepidemiological survey in Southwest of Iran. BMC Infect Dis 2012; 12: 378.
4. Nayagam S, Thursz M, Sicuri E, Conteh L, Wiktor S, Low-Beer D, et al. Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect Dis 2016; 16: 1399-1408.
5. Poorolajal J, Majdzadeh R. Prevalence of chronic hepatitis B infection in Iran: a review article. J Res Med Sci 2009; 14: 249-258.
6. Moghadami M, Dadashpour N, Mokhtari AM, Ebrahimi M, Mirahmadizadeh A. The effectiveness of the national hepatitis B vaccination program 25 years after its introduction in Iran: a historical cohort study. Braz J Infect Dis 2019; 23: 419-426.
7. Das S, Ramakrishnan K, Behera SK, Ganesapandian M, Xavier AS, Selvarajan S. Hepatitis B vaccine and immunoglobulin: Key concepts. J Clin Transl Hepatol 2019; 7: 165-171.
8. Kazemi H, Yadegarynia D, Rashk H. The relation between hepatitis B antibody and number of hepatitis B vaccinations in the personnel of a hospital in Tehran. Res Med 2011; 35: 114-118.
9. Lin Y-C, Chang M-H, Ni Y-H, Hsu H-Y, Chen D-S. Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. J Infect Dis 2003; 187: 134-138.
10. Ma JC, Wu ZW, Zhou HS, Gao Z, Hao ZY, Jin F, et al. Long-term protection at 20-31 years after primary vaccination with plasma-derived hepatitis B vaccine in a Chinese rural community. Hum Vaccin Immunother 2020; 16: 16-20.
11. Mahallawi W. Persistence of hepatitis B surface antibody and immune memory to hepatitis B vaccine among medical college students in Madinah. Ann Saudi Med 2018; 38: 413-419.
12. Williams IT, Goldstein ST, Tufa J, Tauillii S, Margolis HS, Mahoney FJ. Long term antibody response to hepatitis B vaccination beginning at birth and to subsequent booster vaccination. Pediatr Infect Dis J 2003; 22: 157-163.
13. Aghakhani A, Banifazl M, Izadi N, McFarland W, Sofian M, Khadem-Sadegh A, et al. Persistence of antibody to hepatitis B surface antigen among vaccinated children in a low hepatitis B virus endemic area. World J Pediatr 2011; 7: 358-360.
14. Norouzirad R, Shakurnia AH, Assarehzadegan M-A, Serajian A, Khabazkhoob M. Serum levels of anti-hepatitis B surface antibody among vaccinated population aged 1 to 18 years in ahvaz city southwest of Iran. Hepat Mon 2014; 14(1): e13625.
15. Jafarzadeh A, Montazerifar SJ. Persistence of anti-HBs antibody and immunological memory in children vaccinated with hepatitis B vaccine at birth. J Ayub Med Coll Abbottabad 2006; 18: 4-9.
16. Hashemi SMA, Hashemzadeh F, Bahrampour H, Nekoei F, Joharinia N, Sarvari J. The evaluation anti-HBsAb titer among university students in Shiraz, 2019. Iran J Microbiol 2020; 14: 297-306.
17. Norrozi M, Azami A, Sarraf-Neduad A, Chitsaz H, Rahmati N. Persistence of anti-HBs antibody and immune memory to hepatitis B vaccine, 18 years after infantile vaccination in students of Tehran University. Res Med 2016; 40: 36-41.
18. Rezaei M, Nooripoor S, Ghorbani R, Ramezanshams F, Mamishi S, Mahmoudi S. Seroprotection after hepatitis B vaccination in children aged 1 to 15 years in central province of Iran, Semnan. J Prev Med Hyg 2014; 55: 1-3.
19. Said ZN, Abdelwahab KS. Induced immunity against hepatitis B virus. World J Hepatol 2015; 7: 1660-1670.
20. Arias-Moliz MT, Rojas L, Liébana-Cabanillas F, Bernal C, Castillo F, RodrÃguez-Archilla A, et al. Serologic control against hepatitis B virus among dental students of the University of Granada, Spain. Med Oral Patol Oral Cir Bucal 2015; 20(5): e566-71.
21. Sahana H, Sarala N, Prasad S. Decrease in anti-HBs antibodies over time in medical students and healthcare workers after hepatitis B vaccination. Biomed Res Int 2017; 2017: 1327492.
22. Mahmood S, Shah KU, Khan TM. Immune persistence after infant hepatitis-B vaccination: a systematic review and meta-analysis. Sci Rep 2018; 8: 12550.
| Files | ||
| Issue | Vol 15 No 5 (2023) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/ijm.v15i5.13876 | |
| Keywords | ||
| Vaccines; Hepatitis B; Anti-hepatitis B antigens; Medical students | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
